EFFECT OF DOPAMINERGIC MEDICATION ON RISK PREFERENCE IN PARKINSON'S DISEASE

被引：0
|
作者：
Mandali, Alekhya [1 ]
Chaudhuri, Ray [2 ]
Rizos, Alexandra [2 ]
Voon, Valerie [1 ]
机构：
[1] Univ Cambridge, Dept Psychiat, Cambridge, England
[2] Kings Coll London, Ctr Excellence Parkinsons & Movement Disorders, London, England
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2019年 / 90卷
关键词：
D O I：
10.1136/jnnp-2019-BNPA.43
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
43
引用
收藏
页码：A20 / A21
页数：2
相关论文
共 50 条
  • [41] Effect of disease, freezing of gait, and dopaminergic medication in the biomechanics of trunk and upper limbs in the gait of Parkinson's disease
    Los Angeles, Emanuele
    de Oliveira, Claudia Eunice Neves
    Cupertino, Layla
    Shokur, Solaiman
    Bouri, Mohamed
    Coelho, Daniel Boari
    HUMAN MOVEMENT SCIENCE, 2024, 96
  • [42] Short-term effect of dopaminergic medication on speech in early-stage Parkinson’s disease
    Tereza Tykalova
    Michal Novotny
    Evzen Ruzicka
    Petr Dusek
    Jan Rusz
    npj Parkinson's Disease, 8
  • [43] Short-term effect of dopaminergic medication on speech in early-stage Parkinson's disease
    Tykalova, Tereza
    Novotny, Michal
    Ruzicka, Evzen
    Dusek, Petr
    Rusz, Jan
    NPJ PARKINSONS DISEASE, 2022, 8 (01)
  • [44] Computerized assessment of Handwriting in Parkinson's Disease Before and After Dopaminergic Medication
    Diaz-Feliz, L.
    Sanz-Cartagena, P.
    Faundez-Zanuy, M.
    Arbelo-Gonzalez, J.
    Garcia-Ruiz, P.
    MOVEMENT DISORDERS, 2023, 38 : S605 - S605
  • [45] Influence of Dopaminergic Medication on Conditioned Pain Modulation in Parkinson's Disease Patients
    Grashorn, Wiebke
    Schunke, Odette
    Buhmann, Carsten
    Forkmann, Katarina
    Diedrich, Sabrina
    Wesemann, Katharina
    Bingel, Ulrike
    PLOS ONE, 2015, 10 (08):
  • [46] The Impact of Non-dopaminergic Medication on Quality of Life in Parkinson’s Disease
    Nicol G. M. Oonk
    Kris L. L. Movig
    Job van der Palen
    Henk-Willem Nijmeijer
    Mirjam E. van Kesteren
    Lucille D. A. Dorresteijn
    Clinical Drug Investigation, 2021, 41 : 809 - 816
  • [47] Effects of aging, Parkinson's disease, and dopaminergic medication on response selection and control
    Willemssen, Rita
    Falkenstein, Michael
    Schwarz, Michael
    Mueller, Thomas
    Beste, Christian
    NEUROBIOLOGY OF AGING, 2011, 32 (02) : 327 - 335
  • [48] Dopaminergic medication reduces striatal sensitivity to negative outcomes in Parkinson's disease
    McCcoy, Bronagh
    Jahfari, Sara
    Engels, Gwenda
    Knapen, Tomas
    Theeuwes, Jan
    BRAIN, 2019, 142 : 3605 - 3620
  • [49] Speech and Manual Reaction Time as a Function of Dopaminergic Medication in Parkinson's Disease
    McAllen, Audra W.
    Spencer, Kristie A.
    France, Kristin N.
    Shulein, Orli M.
    JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY, 2010, 18 (03) : 59 - 77
  • [50] Dopaminergic medication shifts the balance between going and stopping in Parkinson's disease
    Wylie, Scott A.
    van Wouwe, Nelleke C.
    Godfrey, Steven G.
    Bissett, Patrick G.
    Logan, Gordon D.
    Kanoff, Kristen E.
    Claassen, Daniel O.
    Neimat, Joseph S.
    van den Wildenberg, Wery P. M.
    NEUROPSYCHOLOGIA, 2018, 109 : 262 - 269
12345